Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Workday Inc (WDAY) Price & Performance

Cassava Sciences IncTrade
Workday IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Workday Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Workday Inc trades at $175.29 (market cap $44.77B). The key difference: Workday Inc is far larger — about 937.6× Cassava Sciences Inc's market cap, and Workday Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAWDAY
Market Cap
$47.75M$44.77B
Sector
HealthTechnology
52-Week High
$4.64$247.69
52-Week Low
$0.87$112.55
Enterprise Value
-$34.93M$44.22B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Workday Inc

Workday (WDAY) trades at $174.53, down 5.24% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust revenue growth, reaching $8.45B in 2025 with consistent earnings beats. Recent partnerships and AI product launches, including Workday Learning and FedRAMP authorization, highlight strategic expansion. Analyst consensus remains positive with 55.6% buy ratings despite a recent downgrade from Morgan Stanley on July 21, 2026.

WDAY's outlook is supported by solid fundamentals and AI-driven growth initiatives, though elevated valuation metrics (P/E 56.47) and institutional selling pose risks. The stock faces near-term pressure from overbought technical indicators but maintains long-term potential through enterprise software demand and market leadership in HR/finance solutions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Workday Inc

Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.

Read more on WDAY